About Apricus Biosciences
Apricus Biosciences is a Healthcare company based in San Diego (United States). Apricus Biosciences is focused on innovative drug delivery systems. It operates on a HealthTech model. Apricus Biosciences has completed 1 acquisition, including Novadel Pharma. Apricus Biosciences offers products and services including Vitaros and RayVa. Its focus areas include Biotechnology and Drug Delivery Systems. Its competitors include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Apricus Biosciences, Inc. is engaged in the development and commercialization of innovative drug delivery systems. The company operates within the healthcare sector, specifically in biotechnology, focusing on patient-friendly drugs. Key products like Vitaros and RayVa are developed to address specific medical needs through advanced delivery mechanisms. Business development and investor relations are maintained to support growth and stakeholder engagement.
- Headquarters San Diego, United States
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website apricusbio.com
- Latest Funding Round$3.69M (USD), Post-IPO
Sep 2017
- InvestorsAbbott
& 2 more
- Investments & Acquisitions
Products & Services of Apricus Biosciences
Apricus Biosciences offers a comprehensive portfolio of products and services, including Vitaros and RayVa.
A patient-friendly drug delivery system is provided by Vitaros.
Innovative drug delivery solutions are offered through RayVa product.
Funding Insights of Apricus Biosciences
- Total Rounds 5
- Last Round Post-IPO — $3.69M
- First Round $2.3M
(Feb 2010)
- Investors Count 3
All 5 funding rounds of Apricus Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $3.69M | Post-IPO | – | – | – |
| Mar 2016 | $10M | Post-IPO | – | – | |
| Oct 2012 | $2.5M | Post-IPO | – | – | |
| Mar 2010 | $4M | Debt – Convertible | – | – | – |
| Feb 2010 | $2.3M | Debt – Convertible | – | – | – |
3 investors in total: 3 institutional.
Investors in Apricus Biosciences
Apricus Biosciences has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Abbott, Sarissa Capital Management and Aspire Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| aspirecapital.com | ||||
Investment management firm providing capital services and financial statements. | 2012 | sarissacap.com | Greenwich, United States | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | abbott.com | Libertyville, United States |
Investor details for Apricus Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Apricus Biosciences
Apricus Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Novadel Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical development is conducted in the United States. | novadel.com | Flemington, United States | 2004 | Feb 2012 | •••• |
Complete acquisition details for Apricus Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Apricus Biosciences
4 dated milestones of Apricus Biosciences across 14 years, from founding to its latest funding, stage changes and deals.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.3M.
- Acquisition Acquires Novadel Pharma.
- Funding Latest funding round, Post-IPO, of $3.7M.
Competitors of Apricus Biosciences
Apricus Biosciences has 3 listed competitors in our database, 3 of them funded. They include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| scynexis.com | 1999 | Jersey, United States | $62.65M | 50 | Developing glucan synthase inhibitors for the treatment of fungal infections. | |
| amplyx.com | 2006 | San Diego, United States | $144.31M | 15 | Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma. | |
| eliontx.com | 2024 | New York, United States | $81M | Therapeutics for invasive fungal infections are developed by Elion Therapeutics. |
Detailed competitors of Apricus Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Apricus Biosciences
Websites that share an audience with Apricus Biosciences (apricusbio.com).
Websites whose visitors overlap most with Apricus Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aprea.com | 100% | 5.1K | #3,297,251 | View details | |
| galenabiopharma.com | 100% | View details | |||
| valeritas.com | 99% | View details | |||
| anthera.com | 98% | View details | |||
| khandelwallab.com | 88% | 6.5K | #1,877,524 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Apricus Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Apricus Biosciences (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Apricus Biosciences
Complete news archive for Apricus Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apricus Biosciences
Apricus Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Apricus Biosciences, Inc. is engaged in the development and commercialization of innovative drug delivery systems. The company operates within the healthcare sector, specifically in biotechnology, focusing on patient-friendly drugs. Key products like Vitaros and RayVa are developed to address specific medical needs through advanced delivery mechanisms. Business development and investor relations are maintained to support growth and stakeholder engagement.
Apricus Biosciences's top competitors include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics.
Apricus Biosciences offers Vitaros and RayVa.
Apricus Biosciences has made 1 acquisition, including Novadel Pharma.
Apricus Biosciences has 3 investors. Key investors include Abbott, Sarissa Capital Management, and Aspire Capital.